16 results for "TGF-beta RI/ALK-5 Small Molecules and Peptides" in Products
TGF-beta RI/ALK-5 Small Molecules and Peptides
Most cell types express three sizes of receptors for TGF-beta. These are designated Type I (53 kDa), Type II (70 - 85 kDa), and Type III (250 - 350 kDa). The Type I receptor is a membrane-bound serine/threonine kinase that apparently requires the presence of the Type II receptor to bind TGF-beta. The Type II receptor is also a membrane-bound serin...
Potent, selective inhibitor of TGF-βRI, ALK4 and ALK7
| Chemical Name: | 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide |
| Purity: | ≥99% |
SB 431542 synthesized to cGMP guidelines
| Chemical Name: | 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide |
| Purity: | ≥99% |
Potent and selective inhibitor of TGF-βRI
| Alternate Names: | E-616452,SJN 2511,ALK5 Inhibitor II |
| Chemical Name: | 2-(3-(6-Methylpyridine-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine |
| Purity: | ≥99% |
RepSox synthesized to Ancillary Material Grade
| Alternate Names: | ALK5 Inhibitor II,SJN 2511,E-616452 |
| Chemical Name: | 2-[3-(6-Methylpyridin-2-yl)-1H-pyrazol-4-yl]-1,5-naphthyridine |
| Purity: | ≥99% |
ALK4 and ALK5 (TGFβRI) inhibitor
| Alternate Names: | LY 2157299 |
| Chemical Name: | 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide |
| Purity: | ≥98% |
Selective inhibitor of TGF-βRI, ALK4 and ALK7
| Chemical Name: | 2-[4-(1,3-Benzodioxol-5-yl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-6-methyl-pyridine |
| Purity: | ≥98% |
Potent TGF-βRI inhibitor
| Chemical Name: | 4-[[4-[(2.6-Dimethyl-3-pyridinyl)oxy]-2-pyridinyl]amino]benzenesulfonamide |
| Purity: | ≥98% |
Potent and selective inhibitor of TGF-βRI
| Chemical Name: | 4-[2-Fluoro-5-[3-(6-methyl-2-pyridinyl)-1H-pyrazol-4-yl]phenyl]-1H-pyrazole-1-ethanol |
| Purity: | ≥98% |
Potent and selective inhibitor of TGF-βRI
| Chemical Name: | 3-[[5-(6-Methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl]methyl]benzamide |
| Purity: | ≥98% |
Potent TGF-βRI inhibitor; orally bioavailable
| Chemical Name: | 4-[4-(1,3-Benzodioxol-5-yl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-2-yl]bicyclo[2.2.2]octane-1-carboxamide |
| Purity: | ≥98% |
Selective inhibitor of TGF-βRI, ALK4 and ALK7
| Chemical Name: | 3-(6-Methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide |
| Purity: | ≥98% |
Selective inhibitor of TGF-βRI
| Chemical Name: | 6-[2-(1,1-Dimethylethyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]quinoxaline |
| Purity: | ≥97% |
Potent ATP-competitive TGF-βRI inhibitor
| Chemical Name: | 2-(5-Chloro-2-fluorophenyl)-4-[(4-pyridyl)amino]pteridine |
| Purity: | ≥98% |
Potent and selective inhibitor of TGF-βRI
| Chemical Name: | 4-[4-[3-(2-Pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)-benzamide |
| Purity: | ≥98% |
Selective CK1 inhibitor. Also inhibits TGF-βRI
| Chemical Name: | 4-[4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide |
| Purity: | ≥98% |
A 83-01 synthesized to Ancillary Material Grade
| Chemical Name: | 3-(6-Methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide |
| Purity: | ≥98% |
